MedTrace Logo

Adherence Assessment With Travalert Dosing Aid

NCT00508469 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 102

Last updated 2012-07-12

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to compare adherence in patients on a fixed combination of travoprost 0.004%/timolol 0.5% and patients on a concomitant combination of travoprost 0.004% and timolol 0.5% using the Travalert® device.

Conditions

Interventions

DRUG

Travoprost 0.004%/timolol 0.5% fixed combination eye drops (DuoTrav)

One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.

DRUG

Travoprost 0.004% eye drops

One drop in the study eye once daily at 9 p.m. for six months using the Travalert device.

DRUG

Timolol 0.05% eye drops

One drop in the study eye twice daily at 9 a.m. and 9 p.m. for six months using the Travalert device.

DEVICE

Travalert Dosing Aid

Approved device used with study medication to record time of instillation and quantify dosing

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Dr Francisco M. Honrubia · Independent

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2010-01-31
Completion
2010-01-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00508469 on ClinicalTrials.gov